Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1

J. William Higgins, Alice B. Ke and Maciej J. Zamek-Gliszczynski
Drug Metabolism and Disposition November 2014, 42 (11) 1780-1784; DOI: https://doi.org/10.1124/dmd.114.058784
J. William Higgins
Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice B. Ke
Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maciej J. Zamek-Gliszczynski
Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 42 no. 11 1780-1784
DOI 
https://doi.org/10.1124/dmd.114.058784
PubMed 
25106415

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received April 26, 2014
  • Accepted August 8, 2014
  • Published online September 24, 2014.

Article Versions

  • Earlier version (August 8, 2014 - 08:35).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. J. William Higgins,
  2. Alice B. Ke1, and
  3. Maciej J. Zamek-Gliszczynski2
  1. Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  1. Address correspondence to:
    Dr. Maciej J. Zamek-Gliszczynski, GlaxoSmithKline, 5 Moore Drive, RTP, NC 27709. E-mail: maciej.x.zamek-gliszczynski{at}gsk.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2014 to January 2021

AbstractFullPdf
Aug 20144462131
Sep 20144971164
Oct 20147333184
Nov 20142141039
Dec 2014115613
Jan 20151081522
Feb 2015692220
Mar 2015421311
Apr 201550924
May 2015511422
Jun 2015601613
Jul 201553108
Aug 2015291613
Sep 2015401518
Oct 2015281830
Nov 2015171932
Dec 2015292117
Jan 2016281420
Feb 2016172620
Mar 2016152026
Apr 2016475720
May 2016323318
Jun 2016203137
Jul 2016142835
Aug 2016202728
Sep 2016152419
Oct 201633619
Nov 201655046
Dec 201613233
Jan 201732617
Feb 201713923
Mar 201705126
Apr 201701815
May 201752629
Jun 201763525
Jul 201701733
Aug 20170169
Sep 201713010
Oct 201714735
Nov 201726731
Dec 201702341
Jan 20185336
Feb 201833414
Mar 201852411
Apr 201812823
May 201833413
Jun 201804011
Jul 201833118
Aug 20180238
Sep 201842612
Oct 201842512
Nov 201814417
Dec 201816621
Jan 201926416
Feb 201934816
Mar 20193297
Apr 201952623
May 201912323
Jun 201911716
Jul 20191215
Aug 201932417
Sep 201982614
Oct 20193334
Nov 20193164
Dec 2019181513
Jan 202073227
Feb 202022317
Mar 202033313
Apr 20201168
May 202031213
Jun 20206288
Jul 20200158
Aug 2020095
Sep 202081610
Oct 202023135
Nov 20203931
Dec 20204853
Jan 2021310

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 42 (11)
Drug Metabolism and Disposition
Vol. 42, Issue 11
1 Nov 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

CYP3A Inhibitors Are Not Transported by OATP or OCT

J. William Higgins, Alice B. Ke and Maciej J. Zamek-Gliszczynski
Drug Metabolism and Disposition November 1, 2014, 42 (11) 1780-1784; DOI: https://doi.org/10.1124/dmd.114.058784

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Rapid CommunicationShort Communication

CYP3A Inhibitors Are Not Transported by OATP or OCT

J. William Higgins, Alice B. Ke and Maciej J. Zamek-Gliszczynski
Drug Metabolism and Disposition November 1, 2014, 42 (11) 1780-1784; DOI: https://doi.org/10.1124/dmd.114.058784
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results/Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more SHORT COMMUNICATIONS

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics